Mitsubishi UFJ Asset Management Co. Ltd. Increases Stake in Abbott Laboratories $ABT

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,998,412 shares of the healthcare product maker's stock after purchasing an additional 99,019 shares during the period. Abbott Laboratories makes up about 0.6% of Mitsubishi UFJ Asset Management Co. Ltd.'s portfolio, making the stock its 24th biggest position. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.40% of Abbott Laboratories worth $869,133,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Brighton Jones LLC increased its position in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its position in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares during the period. United Bank increased its holdings in shares of Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC raised its stake in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock worth $1,618,000 after purchasing an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after purchasing an additional 292,547 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company's stock, valued at $2,846,504.24. This represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last ninety days. Company insiders own 0.46% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ABT. Mizuho cut their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Evercore cut their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group cut their price target on Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating on the stock in a research report on Wednesday, April 8th. Finally, Freedom Capital raised Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $119.43.

Abbott Laboratories Trading Down 0.4%

Shares of Abbott Laboratories stock opened at $87.18 on Wednesday. Abbott Laboratories has a fifty-two week low of $86.16 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market cap of $151.84 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The firm has a 50-day simple moving average of $103.83 and a two-hundred day simple moving average of $115.68.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.9%. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.